文献速递类风湿关节炎

已确诊类风湿关节炎临床缓解患者关节损伤进展与严格缓解的预测因素

Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究纳入171例DAS28-CRP<3.2且无肿胀关节的已确诊RA患者,随机接受传统或MRI靶向治疗策略。基线MRI骨炎独立预测2年MRI侵蚀、关节间隙狭窄及联合损伤进展,腱鞘炎预测MRI侵蚀进展;年龄和性别分别预测放射学侵蚀和关节间隙狭窄进展。MRI靶向策略及低患者报告结局评分、低压痛关节数独立预测严格缓解达标。

要点

  • 基线MRI骨炎独立预测2年MRI侵蚀、关节间隙狭窄和联合损伤进展。
  • 基线MRI腱鞘炎独立预测2年MRI侵蚀进展。
  • MRI靶向治疗策略及低压痛关节数、低患者报告结局评分预测严格缓解达标。

核心结论

  • 基线MRI骨炎和腱鞘炎是RA临床缓解患者2年MRI损伤进展的独立预测因素。
  • 放射学损伤进展的独立预测因素为年龄和性别。
  • MRI靶向治疗策略及低患者报告结局评分、低压痛关节数预测严格缓解达标。

研究设计与样本

  • 研究纳入171例已确诊RA且临床缓解(DAS28-CRP<3.2、无肿胀关节)并接受传统合成DMARDs的患者。
  • 患者随机接受传统或MRI靶向达标治疗策略,采用预设算法进行治疗升级。
  • 采用多变量逻辑回归分析检验潜在预测基线变量。

主要发现

  • 基线MRI骨炎独立预测MRI侵蚀进展(OR 1.13,95%CI 1.06–1.22)、关节间隙狭窄进展(OR 1.15,95%CI 1.07–1.24)和联合损伤进展(OR 1.23,95%CI 1.13–1.37)。
  • 基线MRI腱鞘炎独立预测MRI侵蚀进展(OR 1.13,95%CI 1.03–1.25)。
  • 年龄是放射学侵蚀进展的预测因素,性别是关节间隙狭窄进展的预测因素。
  • MRI靶向达标治疗策略预测严格缓解:CDAI缓解OR 2.94(95%CI 1.25–7.52),SDAI缓解OR 2.50(95%CI 1.01–6.66),ACR/EULAR布尔缓解OR 5.47(95%CI 2.33–14.13)。
  • 低压痛关节数及低患者VAS疼痛和整体评分独立预测更严格缓解的达标。

关键数值与推荐

  • 临床缓解定义为DAS28-CRP<3.2且无肿胀关节。
  • MRI靶向达标治疗策略相比传统策略的严格缓解OR值:CDAI缓解2.94(95%CI 1.25–7.52)、SDAI缓解2.50(95%CI 1.01–6.66)、ACR/EULAR布尔缓解5.47(95%CI 2.33–14.13)。
  • 基线MRI骨炎每单位增加的OR值:MRI侵蚀进展1.13(95%CI 1.06–1.22)、关节间隙狭窄进展1.15(95%CI 1.07–1.24)、联合损伤进展1.23(95%CI 1.13–1.37)。
  • 基线MRI腱鞘炎每单位增加的MRI侵蚀进展OR值为1.13(95%CI 1.03–1.25)。

临床怎么用

  • 对已确诊RA临床缓解患者,基线MRI骨炎和腱鞘炎可提示2年MRI损伤进展风险较高。
  • 采用MRI靶向达标治疗策略可能提高严格缓解(CDAI、SDAI、ACR/EULAR布尔缓解)的达标率。
  • 低压痛关节数和低患者报告结局评分提示更易达到严格缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy. METHODS: RA patients (DAS28-CRP <3.2, no swollen joints) receiving conventional synthetic DMARDs were randomized to conventional or MRI-targeted treat-to-target strategies with predefined algorithmic treatment escalations. Potentially predictive baseline variables were tested in multivariate logistic regression analyses. RESULTS: In the 171 patients included, baseline MRI osteitis independently predicted progression in MRI erosion [odds ratio (OR) 1.13 (95% CI 1.06, 1.22)], joint space narrowing [OR 1.15 (95% CI 1.07, 1.24)] and combined damage [OR 1.23 (95% CI 1.13, 1.37)], while tenosynovitis independently predicted MRI erosion progression [OR 1.13 (95% CI 1.03, 1.25)]. A predictor of radiographic erosion progression was age, while gender predicted progression in joint space narrowing. Following an MRI treat-to-target strategy predicted stringent remission across all remission definitions: Clinical Disease Activity Index remission OR 2.94 (95% CI 1.25, 7.52), Simplified Disease Activity Index remission OR 2.50 (95% CI 1.01, 6.66), ACR/EULAR Boolean remission OR 5.47 (95% CI 2.33, 14.13). Similarly, low tender joint count and low patient visual analogue scale pain and global independently predicted achievement of more stringent remission. CONCLUSION: Baseline MRI osteitis and tenosynovitis were independent predictors of 2 year MRI damage progression in RA patients in clinical remission, while independent predictors of radiographic damage progression were age and gender. Following an MRI treat-to-target strategy, low scores of patient-reported outcomes and low tender joint count predicted achievement of stringent remission. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01656278.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Møller-Bisgaard S, Georgiadis S, Hørslev-Petersen K, et al. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology (Oxford). 2021. PMID: 32929463. doi:10.1093/rheumatology/keaa496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。